Clinical Trial

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 26, 2024 (before its estimated March 29, 2025 completion). Its status may not reflect the trial's current state.
Summary
This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission after neoadjuvant therapy. TNBC patients who did not achieve pathological complete remission or positive lymph node after neoadjuvant chemotherapy received adjuvant treatment with study drug. Solution: UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Trial Details
NCT Number NCT06385990
Lead Sponsor Hunan Cancer Hospital
Conditions Triple Negative Breast Neoplasms
Enrollment 53 participants
Start Date 2024-03-29
Primary Completion 2025-03-29 (estimated)
Study Completion 2027-03-29 (estimated)
Updated on ClinicalTrials.gov 2024-04-26